Company Overview of Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases; and obesity, including obesity caused by genetic deficiencies in the MC4 pathway. Its portfolio includes relamorelin (RM-131), a ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes and other GI functional disorders; and RM-493, a melanocortin-4 (MC4) receptor agonist for the treatment of obesity and obesity caused by genetic deficiencies in the MC4 pathway. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is based in Boston, Massachusetts.
855 Boylston Street
Boston, MA 02116
Founded in 2008
Key Executives for Rhythm Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Founder and Chief Development Officer
Compensation as of Fiscal Year 2015.
Rhythm Pharmaceuticals, Inc. Key Developments
Rhythm Pharmaceuticals Inc. Presents at BIO International Convention, Jun-25-2014 10:30 AM
Jun 17 14
Rhythm Pharmaceuticals Inc. Presents at BIO International Convention, Jun-25-2014 10:30 AM. Venue: San Diego Convention Center, San Diego, California, United States.
Rhythm Pharmaceuticals Inc. Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant
Sep 24 13
Rhythm Pharmaceuticals Inc. announced the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway. This RM-493 clinical trial is a new approach that targets the root cause of obesity in the MC4 heterozygote population. MC4R deficiency due to mutations in the MC4R gene has been identified as the most common monogenic cause of obesity. Up to 6% of people with a BMI >35 have MC4R deficiency, and this group has a higher predisposition than the general population for severe obesity and its complications, such as diabetes. MC4R deficiency also correlates with early-onset obesity, which lengthens exposure to the risk of obesity-associated diseases. Furthermore, MC4R deficiency may also undermine the beneficial effects of diet and exercise for weight loss, limiting treatment options for these individuals. This first MC4R deficiency trial is a Phase 1B study designed to evaluate the effect of RM-493 on weight loss and safety in obese patients with a loss-of-function variant of the MC4R gene. Patients will be treated for up to four weeks with RM-493. This study expands on Rhythm's ongoing Phase 2 clinical program for RM-493 for the treatment of obesity. RM-493 has demonstrated impressive efficacy on weight loss in both preclinical studies and early clinical trials in subjects with normal, fully functioning MC4R genes. This new clinical study a personalized medicine approach to the treatment of obesity in people with a poorly functioning MC4R gene and has the potential to restore function in this pathway and improve weight regulation. The company is excited about the potential to address this significant unmet need in metabolic disease. RM-493 is a small-peptide melanocortin 4 receptor (MC4R) agonist that is in clinical development for the treatment of obesity and diabetes. The MC4 receptor mediates a key pathway in humans that regulates energy homeostasis and food intake. The MC4R pathway is well validated in humans; loss-of-function mutations of MC4R are associated with obesity and have a reported prevalence of 4%-6% in severe obesity. In the MC4R heterozygote population, RM-493 may restore MC4R function by increasing activity in the one healthy copy of MC4R.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries